Project Grant R21NS135769

Award Date 9/18/23
Completion Date 8/31/25
Dollars Obligated $425K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53201, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to understand the molecular mechanisms regulating axon regeneration after spinal cord injury. The $1,006,322 award to the University of California, San Diego will fund experiments using a novel patch-based single-cell RNA sequencing approach to refine a regeneration...
This federal Project Grant award for $586,525.00, awarded on August 15, 2024 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the development of a non-invasive infrared light therapy and medical device to treat spinal cord injury. The primary research aims to attenuate the acute injury and inflammatory response in the initial 24 hours following spinal...
This $391,250 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research aimed at developing effective therapeutic strategies for spinal cord injury (SCI) recovery. The key objectives are to: 1) Temporally regulate PTEN (phosphatase and tensin homolog) knockdown after SCI to promote axon regeneration while avoiding...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $234,949 to Yale University to conduct research on mechanisms that support raphespinal tract plasticity and regeneration after spinal cord injury. The objectives are to use anatomy, spatial transcriptomics, and intersectional in vivo chemogenetics to define the capacity and...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $291,020 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of Colorado-Denver to investigate the role of Wnt signaling effectors in regulating the neuron-glia switch and oligodendrocyte progenitor cell (OPC) specification during development and after spinal cord injury. The project will utilize zebrafish models, immunohistochemistry,...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Ohio State University a Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The $566,089 award, effective September 20, 2024 through August 31, 2029, supports research to understand the effects of pneumonia on spinal cord injury recovery. The project aims to identify circulating factors and spinal cord-specific mechanisms that...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to further develop and optimize optogenetic spinal cord stimulation as a therapeutic strategy for promoting functional recovery in rats with severe spinal cord injuries. The $327,824 award, effective July 1, 2024 through June 30, 2029, will support research conducted...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research focused on understanding the role of specific inhibitory interneurons in spinal cord circuits and their potential to improve locomotor function following spinal cord injury. The $291,284 award, granted to Drexel University, will fund a 2-year research...
The National Institutes of Health's National Institute of Neurological Disorders and Stroke awarded The Ohio State University a $119,018 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders program. This grant will support research into strategies to interrogate and enhance myelin remodeling in distal tissue after spinal cord injury. The goal of the NINDS program is to fund basic and applied research exploring the brain, nervous system structure...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, funds research at Tufts University to develop a hybrid differentiation strategy for generating region-specific neural and oligodendrocyte cell populations from human pluripotent stem cells. The project aims to optimize protocols for rapidly differentiating region-specific...

This $424,875.00 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund a comprehensive study of gene transcription patterns in diverse classes of neurons that connect the brain to the spinal cord after spinal cord injury in a mouse model. The research team at Marquette University will use single-cell sequencing technologies to profile baseline molecular differences across these "supraspinal" neuron populations and track how their gene expression changes in response to spinal cord injury. They will also investigate the effects of a transcription factor called SOX11 that has shown potential to promote axon regeneration or cell death depending on the neuron type. This work aims to yield new insights into the cellular complexity underlying spinal cord injury and identify promising targets for future therapeutic interventions. The award period runs from September 2023 through August 2025.

Generated 8/13/24, 2:56 AM